Stallergenes goes outside for innovation
This article was originally published in Scrip
Executive Summary
French allergy company Stallergenes' CEO Robert Gradnik says his company's latest deal, with small Belgian biotech firm ActoGenix, is an illustration of Stallergenes' commitment to innovation, and a statement which acknowledges that "we have understood that innovation doesn't only happen internally, and we have to go outside and network to collaborate."